Neuromyelitis optica spectrum disorder (patient information)
Jump to navigation
Jump to search
|
Neuromyelitis optica spectrum disorder Microchapters |
|
Differentiating Neuromyelitis optica spectrum disorder from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Neuromyelitis optica spectrum disorder (patient information) On the Web |
|
American Roentgen Ray Society Images of Neuromyelitis optica spectrum disorder (patient information) |
|
FDA on Neuromyelitis optica spectrum disorder (patient information) |
|
CDC on Neuromyelitis optica spectrum disorder (patient information) |
|
Neuromyelitis optica spectrum disorder (patient information) in the news |
|
Blogs on Neuromyelitis optica spectrum disorder (patient information) |
|
Directions to Hospitals Treating Neuromyelitis optica spectrum disorder |
|
Risk calculators and risk factors for Neuromyelitis optica spectrum disorder (patient information) |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Julinka Auta Fernandes
For the WikiDoc physician page on this topic, click here.
Overview
- Neuromyelitis optica spectrum disorder (NMOSD) is a rare autoimmune disease in which the immune system mistakenly causes inflammation in the central nervous system, especially the nerves that carry vision from the eyes to the brain (the optic nerves), the spinal cord, and parts of the brainstem.[1][2]
- NMOSD usually causes sudden episodes called attacks or relapses. An attack may cause loss of vision, weakness or numbness, bladder or bowel problems, or severe unexplained vomiting and hiccups. Symptoms often develop over hours to days.[3][4]
- NMOSD is not the same disease as multiple sclerosis (MS). It is also different from myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD). Correct diagnosis matters because the treatments are different.[5][4]
- There is currently no cure, but rapid treatment of attacks and long-term treatment to prevent further attacks can reduce the risk of permanent disability.[6]
What are the symptoms of neuromyelitis optica spectrum disorder?
- You may have one or more of the following groups of symptoms. Symptoms vary according to the part of the nervous system that is inflamed.[1][4]
Symptoms affecting vision
- Inflammation of an optic nerve is called optic neuritis. It may affect one or both eyes and may cause:
- Pain in or behind the eye, sometimes worse with eye movement
- Blurred, dim, or rapidly decreasing vision
- Loss of color vision or colors appearing faded
- A dark or missing area in the field of vision
- Severe or complete loss of vision
Symptoms affecting the spinal cord
- Inflammation of the spinal cord is called transverse myelitis. It may cause:
- Weakness or paralysis of the arms or legs
- Numbness, tingling, burning, or reduced feeling
- A tight, squeezing, or band-like feeling around the chest or abdomen
- Sharp, burning, or shooting nerve pain
- Muscle stiffness, spasms, or painful brief muscle contractions
- Difficulty walking, poor balance, or falls
- Urinary urgency, leakage, difficulty passing urine, or inability to pass urine
- Constipation, loss of bowel control, or sexual problems
- Breathing difficulty if inflammation affects the upper spinal cord
Symptoms affecting the area postrema, brainstem, or brain
- The area postrema is a small part of the lower brain that helps control vomiting. Inflammation in this area may cause repeated or persistent nausea, vomiting, or hiccups without another clear explanation.
- Other brainstem symptoms may include double vision, dizziness or spinning, poor balance, facial numbness or weakness, slurred speech, trouble swallowing, or breathing problems.
- Less commonly, NMOSD may cause marked sleepiness, changes in body temperature or hormone control, confusion, weakness on one side, or seizures. Brain symptoms are particularly important to recognize in children.[5][2]
What causes neuromyelitis optica spectrum disorder?
- NMOSD is an autoimmune disease. This means your immune system attacks part of your own nervous system by mistake.
- Most people with NMOSD have a blood antibody called aquaporin-4 immunoglobulin G (AQP4-IgG). This antibody targets aquaporin-4, a water-channel protein found mainly on support cells in the nervous system called astrocytes. The immune reaction causes inflammation and can secondarily damage myelin, nerve fibers, and other nearby cells.[4][6]
- The reason why the immune system begins making AQP4-IgG is not fully understood. NMOSD is not contagious, and it is not usually inherited in a simple pattern.
- Some patients have no detectable AQP4-IgG. Your specialist must then look carefully for other causes. If myelin oligodendrocyte glycoprotein immunoglobulin G (MOG-IgG) is detected and the clinical criteria are met, the diagnosis is MOGAD rather than NMOSD.[4]
Who is at highest risk?
- NMOSD can affect people of any age, sex, or ethnic background.
- AQP4-IgG-positive NMOSD is much more common in women than in men and most often begins in adulthood, although children and older adults can also develop it.[4]
- NMOSD occurs worldwide. It has a relatively greater burden among people of African, Asian, or Latin American ancestry, but ancestry alone cannot diagnose or predict the disease.
- NMOSD may occur together with another autoimmune condition, such as systemic lupus erythematosus, Sjögren syndrome, autoimmune thyroid disease, or myasthenia gravis.[4]
- These associations are not screening tests. Routine AQP4-IgG testing is not recommended for people without compatible neurological symptoms.
Diagnosis
- NMOSD should be diagnosed by a neurologist, preferably one experienced in neuroimmunology. There is no single scan or symptom that should be interpreted alone. Your doctor combines your history, examination, antibody results, imaging, and tests for other possible diseases.[5][4]
| Test or assessment | What it helps your doctor determine |
|---|---|
| Medical history and neurological examination | Your doctor checks vision, eye movements, strength, feeling, reflexes, balance, walking, coordination, bladder and bowel symptoms, and brainstem function. |
| AQP4-IgG blood test | Serum should be tested for AQP4-IgG using a cell-based assay. A positive result strongly supports NMOSD when you have a compatible attack and other diagnoses have been excluded. If the result is negative but suspicion remains high, your specialist may repeat or confirm testing, particularly if the first sample was taken after immune treatment.[4] |
| MOG-IgG blood test | If AQP4-IgG is negative, your doctor may test serum for MOG-IgG. A positive result must be interpreted with the clinical findings because MOGAD is a separate disease.[4] |
| Magnetic resonance imaging (MRI) | MRI of the brain, optic nerves, and spinal cord—with contrast when appropriate—looks for inflammation and patterns that support NMOSD or suggest another diagnosis.[7] |
| Lumbar puncture | A lumbar puncture, also called a spinal tap, may be used to examine the fluid around your brain and spinal cord. It can show inflammation and help rule out infection, multiple sclerosis, and other conditions. A normal result does not by itself exclude NMOSD. |
| Eye and vision tests | Visual-field testing, color-vision testing, optical coherence tomography (OCT), or visual evoked potentials may measure optic-nerve and retinal injury and provide a baseline for follow-up. |
| Other blood tests | Your doctor may check for infections, nutritional problems, inflammatory conditions, and other autoimmune diseases that can resemble or occur with NMOSD. |
When to seek urgent medical care?
| Seek urgent same-day medical assessment—and emergency care when symptoms are severe—for any possible new NMOSD attack. |
|---|
|
- Early treatment improves the chance of recovery from an attack. Do not wait for a routine appointment if new neurological symptoms appear.[6]
- If you receive eculizumab or ravulizumab, seek emergency care for fever, severe headache, stiff neck, confusion, sensitivity to light, or a new purple or red rash because these medicines increase the risk of life-threatening meningococcal infection. Vaccination lowers but does not remove this risk.[6]
- If you take any treatment that weakens the immune system, contact your medical team promptly for fever or signs of infection. Follow the emergency plan given by your treatment center.
Treatment options
- Treatment has three main goals: stop an attack quickly, prevent future attacks, and manage symptoms or disability. Always follow the plan made with your treating specialist, and do not stop preventive treatment suddenly without medical advice.[6][2]
Treatment of an acute attack
- High-dose corticosteroid medicine, usually methylprednisolone given into a vein, is standard initial treatment.
- Plasma exchange removes harmful antibodies and other inflammatory proteins from the blood. It should be started early when an attack is severe or improvement with corticosteroids is inadequate; specialists may use it promptly together with corticosteroids in severe attacks.
- Immunoadsorption is an alternative blood-filtering treatment at experienced centers. Intravenous immunoglobulin may be considered in selected situations when standard treatment is unsuitable or has not worked, but evidence is more limited.[6]
Long-term prevention of attacks
- Because even one relapse can cause permanent disability, long-term immune treatment is generally recommended after the first attack in AQP4-IgG-positive NMOSD.[6][2]
- Preventive options for AQP4-IgG-positive NMOSD include targeted medicines such as eculizumab, ravulizumab, inebilizumab, and satralizumab. Rituximab is also widely used. Other immune-suppressing medicines, including azathioprine or mycophenolate mofetil, may be used according to your medical history, local approval, availability, and specialist advice.[8][6]
- Treatment for AQP4-IgG-negative NMOSD is individualized because this group is less clearly defined and has less trial evidence. Your doctor should confirm that MOGAD, multiple sclerosis, infection, cancer, and other causes have been excluded.[4][6]
- Some medicines used for multiple sclerosis are ineffective in NMOSD and may worsen it. Do not use or change a multiple-sclerosis medicine unless your specialist has confirmed the diagnosis and treatment plan.[6]
- Before and during preventive treatment, your team may arrange vaccinations and blood tests and may monitor blood-cell counts, liver function, antibody levels, and infections. The exact checks depend on the medicine.
Treatment of symptoms and rehabilitation
- Your care plan may include medicines and rehabilitation for nerve pain, muscle stiffness or spasms, fatigue, bladder or bowel problems, sexual problems, sleep, mood, and other symptoms.
- Physiotherapy, occupational therapy, vision rehabilitation, mobility aids, speech and swallowing therapy, pain care, psychological support, and social support may improve safety and independence.[9]
Where to find medical care for neuromyelitis optica spectrum disorder?
- Ask for care from a neurologist with experience in neuroimmunology or at a center that regularly treats NMOSD. Depending on your symptoms, your team may also include a neuro-ophthalmologist, rehabilitation physician, physiotherapist, occupational therapist, urologist, pain specialist, psychologist, and specialist nurse.
- Children should be assessed by a pediatric neurologist or pediatric neuroimmunology service experienced in inflammatory disorders of the nervous system.
- Reputable information and help locating rare-disease resources are available from:
- If you think you are having an attack, use urgent or emergency services rather than waiting to contact a support organization.
Prevention
- There is no proven way to prevent the first occurrence of NMOSD.
- After diagnosis, the most important way to reduce future disability is to prevent attacks with the long-term treatment prescribed by your specialist.[6]
- Take medicines as prescribed and attend follow-up and safety-monitoring visits. Do not delay an infusion, injection, or tablet or stop treatment without discussing it with your NMOSD team.
- Keep vaccinations up to date according to your specialist's advice. Some vaccines should be given before certain immune treatments when possible. Live vaccines may be unsafe during some treatments.
- Reduce infection risk with good hand hygiene and prompt medical review of fever or infection. Infection can also temporarily worsen old neurological symptoms.
- Discuss pregnancy plans early with your neurologist and obstetrician. Relapse risk may rise after delivery, and some medicines must be timed, changed, or continued carefully. Do not stop treatment simply because you are planning a pregnancy.[6]
- A healthy diet, suitable physical activity, adequate sleep, and avoiding smoking support general health but do not replace preventive immune treatment. No diet, supplement, or alternative therapy has been proven to prevent NMOSD attacks.
What to expect (Outlook/Prognosis)?
- The course of NMOSD varies. Many people—especially those with AQP4-IgG—have a relapsing illness, and a relapse may occur after months or years of stability.[5][4]
- Most lasting disability results from incomplete recovery after attacks rather than slow worsening between attacks. A severe attack can cause permanent visual loss, weakness, or other disability, but early attack treatment can improve recovery.[6]
- Modern preventive treatment has greatly improved the ability to reduce relapses. Your outlook depends on the location and severity of attacks, how quickly treatment begins, recovery after each attack, antibody status, age, other health conditions, and how well preventive treatment controls the disease.[6][2]
- Regular follow-up remains important even when you feel well because a long symptom-free period does not guarantee that the disease will not return.
Possible complications
- Possible complications of NMOSD include:[4][9]
- Partial or complete loss of vision in one or both eyes
- Persistent weakness, paralysis, walking difficulty, falls, or need for a mobility aid
- Long-lasting numbness, nerve pain, muscle stiffness, or painful spasms
- Urinary retention or incontinence, repeated urinary infections, bowel problems, or sexual dysfunction
- Difficulty swallowing, aspiration into the lungs, or breathing failure after severe brainstem or upper spinal-cord attacks
- Fatigue, sleep problems, depression, anxiety, reduced independence, and reduced quality of life
- Blood clots, pressure injuries, bone loss, or infection related to severe immobility
- Side effects of immune treatment, including serious infections; the exact risks depend on the medicine
Sources
- ↑ 1.0 1.1 National Institute of Neurological Disorders and Stroke. Neuromyelitis Optica Spectrum Disorder. National Institutes of Health. Accessed October 20, 2026.
- ↑ 2.0 2.1 2.2 2.3 2.4 Giorgi L, Marignier R, Pique J, et al. French guidelines for the diagnosis and management of neuromyelitis optica spectrum disorder. Revue Neurologique (Paris). Published online July 21, 2026. doi:10.1016/j.neurol.2026.06.004. PMID: 42481362.
- ↑ National Health Service. Neuromyelitis optica (NMO). Page last reviewed December 20, 2024. Accessed October 20, 2026.
- ↑ 4.00 4.01 4.02 4.03 4.04 4.05 4.06 4.07 4.08 4.09 4.10 4.11 4.12 Jarius S, Aktas O, Ayzenberg I, et al. Update on the diagnosis and treatment of neuromyelitis optica spectrum disorders—revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part I: Diagnosis and differential diagnosis. Journal of Neurology. 2023;270(7):3341-3368. doi:10.1007/s00415-023-11634-0. PMID: 37022481.
- ↑ 5.0 5.1 5.2 5.3 Wingerchuk DM, Banwell B, Bennett JL, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. 2015;85(2):177-189. doi:10.1212/WNL.0000000000001729. PMID: 26092914; PMCID: PMC4515040.
- ↑ 6.00 6.01 6.02 6.03 6.04 6.05 6.06 6.07 6.08 6.09 6.10 6.11 6.12 6.13 Kümpfel T, Giglhuber K, Aktas O, et al. Update on the diagnosis and treatment of neuromyelitis optica spectrum disorders—revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part II: Attack therapy and long-term management. Journal of Neurology. 2024;271(1):141-176. doi:10.1007/s00415-023-11910-z. PMID: 37676297.
- ↑ Cortese R, Hacohen Y, Arrambide G, et al. Use of MRI in neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein antibody-associated disease—MAGNIMS consensus recommendations. Nature Reviews Neurology. Published online September 28, 2026. doi:10.1038/s41582-026-01271-2.
- ↑ Paul F, Marignier R, Palace J, et al. International Delphi consensus on the management of AQP4-IgG-positive NMOSD: Recommendations for eculizumab, inebilizumab, and satralizumab. Neurology: Neuroimmunology & Neuroinflammation. 2023;10(4):e200124. doi:10.1212/NXI.0000000000200124. PMID: 37258412; PMCID: PMC10231913.
- ↑ 9.0 9.1 Abboud H, Salazar-Camelo A, George N, et al. Symptomatic and restorative therapies in neuromyelitis optica spectrum disorders. Journal of Neurology. 2022;269(4):1786-1801. doi:10.1007/s00415-021-10783-4. PMID: 34482456.